Saniona AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SANION.ST research report →
Companywww.saniona.com
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders.
- CEO
- Thomas Feldthus
- IPO
- 2014
- Employees
- 22
- HQ
- Glostrup, DK
Price Chart
Valuation
- Market Cap
- $1.85B
- P/E
- 6.51
- P/S
- 4.26
- P/B
- 2.92
- EV/EBITDA
- 4.02
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 77.64%
- Op Margin
- 62.47%
- Net Margin
- 65.53%
- ROE
- 59.19%
- ROIC
- 39.74%
Growth & Income
- Revenue
- $434.40M · 29.80%
- Net Income
- $284.67M · 50.85%
- EPS
- $2.21 · 24.86%
- Op Income
- $274.72M
- FCF YoY
- -19.58%
Performance & Tape
- 52W High
- $28.30
- 52W Low
- $7.91
- 50D MA
- $14.91
- 200D MA
- $16.83
- Beta
- 1.16
- Avg Volume
- 791.56K
Get TickerSpark's AI analysis on SANION.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our SANION.ST Coverage
We haven't published any research on SANION.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SANION.ST Report →